

Special Issue

Musculoskeletal Diseases: Aetiology, Clinical Implications, Rehabilitation and Treatment, 2nd Edition

Message from the Guest Editors

Following the success of the first edition, we are delighted to invite you to participate in this new Special Issue. Musculoskeletal diseases represent a significant challenge for health operators in many sectors of medicine. With this Special Issue, we aim to deepen our knowledge of the diagnosis strategies of these pathologies, their clinical and dysfunctional consequences, and therapy and rehabilitation approaches. We are particularly interested in research on new evaluation tools and therapeutic novelties. Therefore, both original articles and reviews on this topic are welcome. s

Guest Editors

Dr. Giacomo Fari

Department of Experimental Medicine (Di.Me.S.), University of Salento,
73100 Lecce, Italy

Dr. Andrea Bernetti

Department of Experimental Medicine (Di.Me.S.), University of Salento,
73100 Lecce, Italy

Deadline for manuscript submissions

25 March 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/210797

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).